EGFR and neoplasm: EGFR protein overexpression and gene mutation/amplification are known drivers of gliomagenesis and GB aggressiveness, activating signaling cascades that trigger tumor cell proliferation and invasiveness, angiogenesis, and suppressing apoptotic cell death [20, 36–39], largely contributing to the high RT-CHT therapy resistant GB phenotype [6, 39, 40].